One-Year Clinical Outcomes among Patients with Metabolic Syndrome and Acute Myocardial Infarction
暂无分享,去创建一个
M. Jeong | Y. Ahn | Young Jo Kim | M. Cho | C. Kim | S. Chae | T. Hong | I. Seong | J. Chae | K. Seung | Seung‐Jung Park | J. Bae | S. Rha | M. Ji
[1] G. Ferns,et al. Serum Small Dense Low-density Lipoprotein Concentrations are Elevated in Patients with Significant Coronary Artery Stenosis and are Related to Features of the Metabolic Syndrome , 2012, Lipids.
[2] K. Cao,et al. The angiographic and clinical outcomes after coronary stenting in patients with metabolic syndrome. , 2012, Atherosclerosis.
[3] İ. Uslu,et al. Statins improve myocardial perfusion in metabolic syndrome patients who have perfusion defects on myocardial perfusion imaging and angiographically normal coronary arteries. , 2012, European review for medical and pharmacological sciences.
[4] S. Goyal,et al. Impact of metabolic syndrome on re-stenosis development: Role of drug-eluting stents , 2012, Diabetes & vascular disease research.
[5] T. Miyazaki,et al. Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[6] P. Filardi,et al. [Inflammation and lipids in the coronary pathology. Risk factors, causes or therapeutic target?]. , 2010, Giornale italiano di cardiologia.
[7] J. Cho,et al. Impact of the Metabolic Syndrome on the Clinical Outcome of Patients with Acute ST-Elevation Myocardial Infarction , 2010, Journal of Korean medical science.
[8] Doo Sun Sim,et al. Current management of acute myocardial infarction: experience from the Korea Acute Myocardial Infarction Registry. , 2010, Journal of cardiology.
[9] T. Hong,et al. Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation. , 2010, Diabetes research and clinical practice.
[10] Bhawna Singh,et al. Inflammation and dyslipidaemia: a possible interplay between established risk factors in North Indian males with coronary artery disease , 2010, Cardiovascular journal of Africa.
[11] A. Oguz,et al. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. , 2009, Journal of atherosclerosis and thrombosis.
[12] O. Maden,et al. Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction , 2009, Coronary artery disease.
[13] S. Yusuf,et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. , 2009, Journal of the American College of Cardiology.
[14] T. Katagiri,et al. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. , 2008, Journal of atherosclerosis and thrombosis.
[15] R. Blindt,et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. , 2007, The American journal of cardiology.
[16] J. Moon,et al. Lipoprotein(a) and LDL Particle Size Are Related to the Severity of Coronary Artery Disease , 2007, Cardiology.
[17] F. Bonnet,et al. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. , 2007, Atherosclerosis.
[18] S. Devaraj,et al. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. , 2006, The Journal of clinical endocrinology and metabolism.
[19] A. Greenberg,et al. Obesity and the role of adipose tissue in inflammation and metabolism. , 2006, The American journal of clinical nutrition.
[20] R. Krauss,et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.
[21] R. Deckelbaum,et al. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. , 2005, International journal of cardiology.
[22] G. Rioufol,et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. , 2005, Archives of internal medicine.
[23] A. Zwinderman,et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. , 2005, Diabetes care.
[24] P. Deedwania,et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. , 2005, The American journal of cardiology.
[25] C. Cannon,et al. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology , 2004, Current opinion in lipidology.
[26] A. Gotto,et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2004, The American journal of cardiology.
[27] S. Haffner,et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. , 2003, Diabetes care.
[28] K. Mahaffey,et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .
[29] Dean P. Jones,et al. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. , 2012, Journal of clinical lipidology.
[30] L. Masana,et al. Management of Dyslipidemia in the Metabolic Syndrome , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.